Assessing ischemic and bleeding risks after TAVR

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the risks of ischemic and bleeding events in patients undergoing transcatheter aortic valve replacement (TAVR) for severe aortic stenosis. It aims to establish a tailored antithrombotic strategy based on individual patient risk profiles and the type of prosthesis used. The study will analyze data from patients at various surgical risk levels and assess changes in antithrombotic therapy over time. By comparing outcomes, the study seeks to identify optimal treatment approaches to improve patient safety and outcomes.

Why it matters

Who can join: the full rules

Inclusion criteria

* All patients with severe aortic stenosis undergoing TAVR.
* Availability of changes in antithrombotic therapy at 1 month, 90 days, and 1 year after TAVR.

Exclusion Criteria

* Patients who died during the index procedure
* Patients in triple antithrombotic therapy at discharge
* Patients with a known prognosis less than 1 year at the time of TAVR

Where it's running

• OLV Hospital
  Aalst, Belgium Recruiting
• Complejo Asistencial Dr. Sótero del Río
  Santiago, Chile Recruiting
• Cardiocenter, 3rd Medical School, Charles University and University Hospital Kralovske Vinohrady
  Prague, Czechia Recruiting
• ASST GOM Niguarda
  Milan, Italia, Italy Recruiting
• Humanitas Research Hospital
  Rozzano, Milano, Italy Recruiting
• IRCCS Policlinico San Donato
  San Donato Milanese, Milano, Italy Recruiting

Study contacts

• Study coordinator: Giuseppe Esposito, MD
• Email: giuseppe.esposito@yahoo.com
• Phone: +393278393131

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluation of the Point-Guard device during heart valve replacement

  This study is testing a new device called Point-Guard to see if it can help prevent brain problems during heart valve replacement surgery.

  Recruiting Transverse Medical, Inc. · Clayton, Victoria · NCT06962371

• Evaluating the SAPIEN 3 Ultra RESILIA Valve for Aortic Stenosis

  This study tests how well the new SAPIEN 3 Ultra RESILIA valve works for people with severe aortic stenosis who are getting a heart valve replacement, by checking its performance over the next 10 years.

  Recruiting Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · Québec, Quebec · NCT06420830

• Evaluating coronary re-engagement after TAVR with a Navitor valve

  This study is testing if a new way of placing a heart valve during TAVR can help doctors still access the coronary arteries for patients who have both aortic stenosis and coronary artery disease.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT05779787

• Transcatheter Aortic Valve Replacement Registry for Outcomes and Quality Monitoring

  This registry collects information from hospitals about patients undergoing TAVR to see how care and outcomes compare to guidelines and nationwide data.

  Recruiting American College of Cardiology · Washington D.C., District of Columbia · NCT07908355

• SYMmetric Valve expansion to reduce hypoattenuated leaflet thickening after balloon-expandable TAVI

  This trial tests whether the Double-TAP post-dilatation strategy can reduce HALT and improve valve function in patients 70 or older undergoing balloon-expandable TAVI.

  Recruiting Erasmus Medical Center · Düsseldorf and 4 other locations · NCT07872020

• Vericiguat to slow calcific aortic valve narrowing

  This trial tests whether vericiguat can slow the progression of mild-to-moderate calcific aortic valve stenosis compared with placebo.

  Recruiting Phase 2 West China Hospital · Chengdu, Sichuan · NCT07715279

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.